Tauroursodeoxycholate protects from glycochenodeoxycholate-induced gene expression changes in perfused rat liver
Author:
Paluschinski Martha1ORCID, Castoldi Mirco1, Schöler David1, Bardeck Nils1, Oenarto Jessica1, Görg Boris1, Häussinger Dieter1
Affiliation:
1. Clinic for Gastroenterology, Hepatology and Infectious Diseases , Heinrich-Heine-University Düsseldorf , Moorenstraße 5 , 40225 Düsseldorf , Germany
Abstract
Abstract
Tauroursodeoxycholate (TUDC) is well known to protect against glycochenodeoxycholate (GCDC)-induced apoptosis in rat hepatocytes. In the present study, we analyzed whether TUDC also exerts protective effects by modulating GCDC-induced gene expression changes. For this, gene array-based transcriptome analysis and quantitative polymerase chain reaction (qPCR) were performed on RNA isolated from rat livers perfused with GCDC, TUDC or a combination of both (each 20 μm for 2 h). GCDC led to a significant increase of lactate dehydrogenase (LDH) into the effluent perfusate, which was prevented by TUDC. GCDC, TUDC and co-perfusion induced distinct gene expression changes. While GCDC upregulated the expression of several pro-inflammatory genes, co-perfusion with TUDC increased the expression of pro-proliferative and anti-apoptotic p53 target genes. In line with this, levels of serine20-phosphorylated p53 and of its target gene p21 were elevated by GCDC in a TUDC-sensitive way. GCDC upregulated the oxidative stress surrogate marker 8OH(d)G and the pro-apoptotic microRNAs miR-15b/16 and these effects were prevented by TUDC. The upregulation of miR-15b and miR-16 in GCDC-perfused livers was accompanied by a downregulation of several potential miR-15b and miR-16 target genes. The present study identified changes in the transcriptome of the rat liver which suggest, that TUDC is hepatoprotective by counteracting GCDC-induced gene expression changes.
Funder
Deutsche Forschungsgemeinschaft
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference85 articles.
1. Becker, S., Reinehr, R., Graf, D., Vom Dahl, S., and Häussinger, D. (2007). Hydrophobic bile salts induce hepatocyte shrinkage via NADPH oxidase activation. Cell. Physiol. Biochem. 19, 89–98. 2. Belguise, K., Kersual, N., Galtier, F., and Chalbos, D. (2005). FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24, 1434–1444. 3. Benes, V., Collier, P., Kordes, C., Stolte, J., Rausch, T., Muckentaler, M.U., Häussinger, D., and Castoldi, M. (2015). Identification of cytokine-induced modulation of microRNA expression and secretion as measured by a novel microRNA specific qPCR assay. Sci. Rep. 5, 11590. 4. Beuers, U. (2006). Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 318–328. 5. Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G.R., Sauerbruch, T., and Paumgartner, G. (1992). Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16, 707–714.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|